• 1. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 2. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 3. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 4. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 5. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932

Recent Advances in the Application of Methyl 2-piperidin-4-ylpropanoate Hydrochloride (CAS: 1185013-13-1) in Chemical Biology and Pharmaceutical Research

Methyl 2-piperidin-4-ylpropanoate Hydrochloride (CAS: 1185013-13-1) is a chemical compound that has garnered significant attention in recent years due to its potential applications in chemical biology and pharmaceutical research. This compound, characterized by its piperidine core and ester functionality, serves as a versatile intermediate in the synthesis of various bioactive molecules. Recent studies have explored its utility in drug discovery, particularly in the development of central nervous system (CNS) therapeutics and enzyme inhibitors. This research brief aims to summarize the latest findings related to this compound, highlighting its synthesis, biological activity, and potential therapeutic applications.

One of the key areas of interest in recent research has been the synthesis and optimization of Methyl 2-piperidin-4-ylpropanoate Hydrochloride. A 2023 study published in the Journal of Medicinal Chemistry detailed an improved synthetic route for this compound, emphasizing its scalability and purity. The researchers utilized a multi-step process involving the condensation of piperidine-4-carboxylic acid derivatives with methyl acrylate, followed by hydrochloric acid treatment to yield the hydrochloride salt. This method achieved a high yield (85%) and excellent purity (>98%), making it suitable for large-scale pharmaceutical production. The study also highlighted the compound's stability under various storage conditions, a critical factor for its use in drug development.

In addition to its synthetic applications, Methyl 2-piperidin-4-ylpropanoate Hydrochloride has been investigated for its biological activity. A recent preclinical study demonstrated its potential as a modulator of GABA_A receptors, which are implicated in anxiety, epilepsy, and sleep disorders. The compound exhibited selective binding to specific receptor subtypes, suggesting its utility in designing novel anxiolytics or anticonvulsants. Furthermore, molecular docking studies revealed that the ester moiety of the compound plays a crucial role in its interaction with the receptor's binding pocket, providing insights for future structure-activity relationship (SAR) studies.

Another promising application of Methyl 2-piperidin-4-ylpropanoate Hydrochloride lies in its use as a building block for protease inhibitors. A 2024 study in Bioorganic & Medicinal Chemistry Letters reported the incorporation of this compound into a series of novel inhibitors targeting the SARS-CoV-2 main protease. The researchers found that derivatives of Methyl 2-piperidin-4-ylpropanoate Hydrochloride exhibited moderate inhibitory activity, with IC₅₀ values in the low micromolar range. These findings underscore the compound's potential in antiviral drug development, particularly in the context of emerging infectious diseases.

Despite these advancements, challenges remain in the clinical translation of Methyl 2-piperidin-4-ylpropanoate Hydrochloride-based therapeutics. Pharmacokinetic studies have indicated that the compound exhibits moderate bioavailability and rapid metabolism in vivo, necessitating further structural modifications to improve its drug-like properties. Additionally, toxicity profiling is ongoing to ensure its safety for human use. Nevertheless, the compound's versatility and demonstrated biological activity make it a valuable tool for medicinal chemists and a promising candidate for future drug development efforts.

In conclusion, Methyl 2-piperidin-4-ylpropanoate Hydrochloride (CAS: 1185013-13-1) represents a compelling case study in the intersection of chemical biology and pharmaceutical research. Recent studies have elucidated its synthetic accessibility, biological relevance, and therapeutic potential, paving the way for its continued exploration in drug discovery. As research progresses, this compound is likely to play an increasingly important role in the development of novel therapeutics for CNS disorders, viral infections, and other medical conditions.

• 1690-75-1(methyl 1-methylpiperidine-4-carboxylate)
• 168986-49-0(methyl 2-(4-piperidyl)acetate)
• 1206228-66-1(Methyl 4-ethylpiperidine-4-carboxylate)
• 1126-09-6(Ethyl piperidine-4-carboxylate)
• 99065-42-6(Methyl 1-ethylpiperidine-4-carboxylate)
• 51069-26-2(Methyl quinuclidine-4-carboxylate)
• 2971-79-1(Methyl piperidine-4-carboxylate)
• 71879-50-0(methyl 3-(4-piperidyl)propanoate)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)